Scientific Program
 |
Download program in pdf |
| 08:30 |
Welcome Cristiana Sessa ESMO Representative |
|
Manuel Llombart Regional Minister for Health, Valencia, Spain |
|
| 08:45 - 09:25 |
Keynote Lecture: Genomic Analysis Michael J. Birrer · Massachusetts General Hospital, Boston (MA), USA |
| SESSION - 1 - PATHOGENESIS: FROM MORPHOLOGY TO MOLECULAR DIAGNOSIS | |
| Chairs: |
Michael J. Birrer · Massachusetts General Hospital, Boston (MA), USA Ignacio Romero · Fundación Instituto Valenciano de Oncología, Valencia, Spain |
| 09:25 - 09:50 |
Molecular Pathogenesis Robert J. Kurman · The Johns Hopkins Hospital, Baltimore (MD), USA |
| 09:50 - 10:15 |
Clinical Implications Elise C. Kohn · National Cancer Institute, Bethesda (MD), USA |
| 10:15 - 10:25 | Discussion |
| SESSION - 2 - SURGERY IN OVARIAN CANCER | |
| Chairs: |
Nicoletta Colombo · European Institute of Oncology, Milan, Italy Sergi Martínez · Hospital Clínic Universitari, Barcelona, Spain |
| 10:25 - 10:50 |
State of the Art of Surgery in Advanced Ovarian Cancer Neville F. Hacker · Royal Hospital for Women, Randwick, Australia |
| 10:50 - 11:30 | Surgical Intervention in Relapsed Ovarian Cancer is Beneficial |
| 10:50 - 11:05 |
In Favor Philipp Harter · Kliniken Essen-Mitte, Essen, Germany |
| 11:05 - 11:20 |
Contra Maurie Markman · Cancer Treatment Centers of America, Eastern Regional Medical Center, Philadelphia (PA), USA |
| 11:20 - 11:30 | Discussion |
| 11:30 - 12:00 | Coffee Break |
| SESSION - 3 - SYSTEMIC THERAPY IN OVARIAN CANCER: 1st LINE | |
| Chairs: |
Jan B. Vermorken · Antwerp University Hospital, Edegem, Belgium Antonio Casado · Hospital Clínico San Carlos, Madrid, Spain |
| 12:00 - 12:25 |
Do We Have a New Standard in Suboptimal Debulked Disease? Michael A. Bookman · Arizona Cancer Center, Tucson (AZ), USA |
| 12:25 - 12:50 |
Current Situation and New Developments in IP Chemotherapy Joan L. Walker · University of Oklahoma Health Sciences Center, Oklahoma (OK), USA |
| 12:50 - 13:15 |
Update on Non-Serous Ovarian Cancer Trials Keiichi Fujiwara · Saitama Medical University, Saitama, Japan |
| 13:15 - 13:30 | Discussion |
| 13:30 - 15:00 | Lunch |
| SESSION - 4 - SYSTEMIC THERAPY IN OVARIAN CANCER: RECURRENT | |
| Chairs: |
Sandro Pignata · National Cancer Institute, Pascale, Naples, Italy José Mª Del Campo · Hospital General Vall d'Hebron, Barcelona, Spain |
| 15:00 - 15:25 |
Update on Randomized Trials on Recurrent Disease Antonio González · MD Anderson Cancer Center, Madrid, Spain |
| 15:25 - 16:30 | Bevacizumab Should Preferably Be Used in Recurrent Disease |
| 15:25 - 15:45 |
In Favor Eric Pujade-Lauraine · Hôpital Hôtel-Dieu, Paris, France |
| 15:45 - 16:05 |
Contra Bradley J. Monk · St Joseph's Hospital and Medical Center, Phoenix (AZ), USA |
| 16:05 - 16:30 | Discussion |
| 16:30 - 17:00 | Coffee Break |
| SESSION - 5 - NEW DEVELOPMENTS | |
| Chairs: |
Elizabeth Eisenhauer · Queen's University, Kingston (ON), Canada Andrés Cervantes · Hospital Clínico Universitario, Valencia, Spain |
| 17:00 - 17:25 |
Targeted Therapies and Clinical Trials Janet Dancey · Queen's University, Kingston (ON), Canada |
| 17:25 - 17:50 |
Patient Reported Outcome in Clinical Trials Michael Friedlander · Prince of Wales Hospital, Randwick, Australia |
| 17:50 - 18:15 |
New Outlook for the Future Stanley B. Kaye · The Royal Marsden Hospital, London, United Kingdom |
| 18:15 - 18:30 |
Remarks and Conclusions Andrés Poveda · Fundación Instituto Valenciano de Oncología, Valencia, Spain |